<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04256707</url>
  </required_header>
  <id_info>
    <org_study_id>KCP-330-027</org_study_id>
    <nct_id>NCT04256707</nct_id>
  </id_info>
  <brief_title>Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment</brief_title>
  <acronym>SPRINT</acronym>
  <official_title>Open-Label, Phase 1/2 Study Evaluating the Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, and the Tolerability and Antitumor Activity of Selinexor Combination Treatment (SPRINT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karyopharm Therapeutics Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karyopharm Therapeutics Inc</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1/2, two-part, multi-arm, open-label study in patients with normal Hepatic&#xD;
      Function (HF), with either Non-small cell lung cancer (NSCLC), who have had 1-2 prior lines&#xD;
      of treatment, with 1 line containing a checkpoint Inhibitor (CPI); or patients with normal&#xD;
      HF, with colorectal cancer (CRC) who have had 1-3 prior lines (KRAS wild-type [WT]) or 1-2&#xD;
      prior lines (mutant KRAS) of treatment with no CPI; or patients with impaired HF, with any&#xD;
      solid tumor, who have had at least 1 prior line of treatment.&#xD;
&#xD;
      The study will comprise 2 treatment periods (monotherapy and combination therapy).&#xD;
&#xD;
      The purposes of this study, during Monotherapy period, are: (1) to determine the relative&#xD;
      bioavailability of the 100 milligrams (mg) (Tablet B) and 20 mg (Tablet A) tablets of&#xD;
      selinexor at 100 mg once weekly (QW) dose in patients with normal hepatic function; and (2)&#xD;
      to assess the PK of selinexor after a single dose of 40 mg (2 × 20 mg), among patients with&#xD;
      moderate and severe hepatic impairment, relative to 100 mg (5 × 20 mg), among patients with&#xD;
      normal hepatic function; and, during the Combination therapy period, to assess the&#xD;
      preliminary anti-tumor activity of selinexor in combination with docetaxel in patients with&#xD;
      NSCLC and with pembrolizumab or folinic acid, 5-fluorouracil, and irinotecan (FOLFIRI) in&#xD;
      patients with CRC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to 120 patients will be enrolled, of which, 20 with normal HF will be able to continue&#xD;
      from Monotherapy to Combination therapy and up to 106 patients with normal HF will receive&#xD;
      combination therapy in total. Patients with impaired hepatic function can only participate in&#xD;
      the Monotherapy part of the study.&#xD;
&#xD;
      Monotherapy Period:&#xD;
&#xD;
      For the Monotherapy Period of Study KCP-330-027, patients with normal hepatic function&#xD;
      (n=20), will be allocated to one of two test formulation treatment arms, and will receive a&#xD;
      cross-over once weekly oral dosing, with either 1x100 milligrams (mg) or 5x20 mg selinexor,&#xD;
      for 2 weeks, and then will have the option to move on to the combination treatment part of&#xD;
      the study. Patients with either moderately or severely impaired hepatic functions will be&#xD;
      treated with 2x20 mg selinexor weekly (with an option to increase the dose every 3 weeks by&#xD;
      20 mg increments, up to 80 mg).&#xD;
&#xD;
      For Weeks 1 and 2, following an overnight fast of at least 10 hours, patients will be fed a&#xD;
      standard low-fat meal 30 minutes prior to administration of once weekly selinexor. Patients&#xD;
      should finish the meal in 30 minutes or less; however, selinexor dose should be administered&#xD;
      30 minutes after start of the meal.&#xD;
&#xD;
      Blood sampling for selinexor PK analyses will be collected ≤10 minutes (m) pre selinexor&#xD;
      dose, and at 15m (±5m), 30m (±5m), 1 hour (h) (±5m), 1.5h (±5m), 2h (±10m), 3h (±10m), 4h&#xD;
      (±10m), 5h (±10m), 6h (±10m), 8h (±20m), 10h (±20m; optional), 24h (±1h), 30h (±1h), and 48h&#xD;
      (±2h) post selinexor dose. Practitioners must record the actual clock time for selinexor dose&#xD;
      and each sample drawn.&#xD;
&#xD;
      If a patient experiences emesis during the first 6 hours of the PK sampling, the PK results&#xD;
      for that week will be excluded from the PK analysis dataset, and all testing timepoints must&#xD;
      be re-collected during the following week (in this case, the same dosing formulation should&#xD;
      be repeated on the following week, and other dosing formulation will be given the week after&#xD;
      that).&#xD;
&#xD;
      Patients who will complete the Monotherapy Period will be reassessed for continuation to the&#xD;
      Combination Therapy Period, as long as their Hepatic Function remains normal.&#xD;
&#xD;
      If a patient experiences significant toxicity related to selinexor and can't start the&#xD;
      combination therapy immediately following monotherapy, dose interruption and weekly retesting&#xD;
      are allowed for up to 21 days after the end of Monotherapy treatment visit. Patients&#xD;
      requiring &gt;21 days to recover from toxicities related to selinexor should be discussed with&#xD;
      the Sponsor's Medical Monitor for documented approval to continue to the Combination Therapy&#xD;
      Period. Reassessment may be extended then and following Medical Monitor approval up to 28&#xD;
      days.&#xD;
&#xD;
      Combination Therapy Period:&#xD;
&#xD;
      In the combination treatment period of the study, patients with normal hepatic functions will&#xD;
      be allocated to one of 3 arms (with Arm C divided into 2 cohorts): Arm A (n=40): Patients&#xD;
      with NSCLC who have had up to 2 lines of prior systemic treatment with 1 line containing a&#xD;
      CPI will receive 60 mg selinexor weekly, in combination with docetaxel 75 milligrams per&#xD;
      meter square (mg/m^2) once every 3 weeks; Arm B (n=40): Patients with CRC (KRAT WT) who have&#xD;
      had up to 3 lines of prior systemic treatment or patients with CRC (KRAS mutant [KRAS Mut])&#xD;
      who have had up to 2 lines of prior systemic treatment, with no lines containing a checkpoint&#xD;
      inhibitor (CPI) will receive 80 mg selinexor weekly, in combination with pembrolizumab 200 mg&#xD;
      once every 3 weeks; Arm C (n&lt;=26): Patients with CRC (regardless of KRAS status) who have had&#xD;
      up to 2 lines of prior systemic treatment (regardless of CPI use) will receive either:&#xD;
      (Cohort 1) selinexor 40 mg on days 1, 3, 15 and 18 in 28-day cycle + FOLFIRI; or (Cohort 2)&#xD;
      selinexor 80 mg on days 1 and 15 in 28-day cycle + FOLFIRI.&#xD;
&#xD;
      Combination Therapy Period Patients will receive combination treatment until progressive&#xD;
      disease (PD) or intolerable toxicity.&#xD;
&#xD;
      During both study periods, safety will be assessed through continuous reporting of adverse&#xD;
      events (AEs), treatment-emergent adverse events (TEAEs), regularly scheduled clinical&#xD;
      laboratory tests (hematologic and chemical), and physical examinations.&#xD;
&#xD;
      Tumor assessment will be performed with either computed tomography (CT) or magnetic resonance&#xD;
      imaging (MRI) (CT with contrast preferred; for each patient, the imaging method should remain&#xD;
      the same throughout the study).&#xD;
&#xD;
      Following treatment, patients will come in for a safety visit (approximately 30 days after&#xD;
      the last dose of combination therapy) and will be followed for up to 1 year after that.&#xD;
      Patients who discontinued due to PD will be followed for survival, and patients who&#xD;
      discontinued for reasons other than PD will have tumor assessments until PD or until the&#xD;
      start of new anti-neoplastic therapy, after which they will be followed for survival.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 14, 2020</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Two part study (monotherapy period and combination therapy period).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Monotherapy Period: Area Under the Concentration-Time Curve from Time Zero to Time of Last Concentration (AUC 0-t) of Selinexor in Patients with Normal, Moderate and Severe Hepatic Function</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Monotherapy Period: Area Under the Concentration-Time Curve from Time Zero Extrapolated to Infinity (AUC 0-inf) of Selinexor in Patients with Normal, Moderate and Severe Hepatic Function</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Monotherapy Period: Maximum Plasma Concentration (Cmax) of Selinexor in Patients with Normal, Moderate and Severe Hepatic Function</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Combination Therapy Period: Arm A and B: Overall Response Rate (ORR) as Assessed by Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1)</measure>
    <time_frame>Up to 36 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Combination Therapy Period: Arm C: Number of Patients With Adverse Events (AEs)</measure>
    <time_frame>From start of study drug administration up to survival follow-up (Up to 36 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Monotherapy Period: Time to Maximum Observed Concentration (Tmax) of Selinexor in Patients with Normal, Moderate and Severe Hepatic Impairment</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monotherapy Period: Terminal Elimination Rate Constant (Lambda z) of Selinexor in Patients with Normal, Moderate and Severe Hepatic Impairment</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monotherapy Period: Terminal Half-Life (t1/2) of Selinexor in Patients with Normal, Moderate and Severe Hepatic Impairment</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monotherapy Period: Apparent Clearance (CL/F) of Selinexor in Patients with Normal, Moderate and Severe Hepatic Impairment</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monotherapy Period: Apparent Volume of Distribution (Vd/F) of Selinexor in Patients with Normal, Moderate and Severe Hepatic Impairment</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monotherapy Period: Fraction Unbound (fu) of Selinexor (Tablet A) in Plasma</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monotherapy Period: Maximum Free-Drug Concentration (Cmaxu) of Selinexor (Tablet A) in Plasma</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monotherapy Period: Area Under the Free-Drug Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUCu) of Selinexor (Tablet A) in Plasma</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monotherapy Period: Apparent Free-drug Clearance (CLu/F) of Selinexor (Tablet A) in Plasma</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monotherapy Period: Apparent Free-drug Volume of Distribution (Vu/F) of Selinexor (Tablet A) in Plasma</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combination Therapy Period: Progression-free Survival (PFS): Arms A and C as Assessed by RECIST 1.1 and Arm B as Assessed by iRECIST</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combination Therapy Period: Duration of Response (DOR): Arms A and C as Assessed by RECIST 1.1 and Arm B as Assessed by iRECIST</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combination Therapy Period: Disease Control Rate (DCR): Arms A and C: as Assessed by RECIST 1.1 and Arm B as Assessed by iRECIST</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combination Therapy Period: Overall Survival (OS): Arms A and C as Assessed by RECIST 1.1 and Arm B as Assessed by iRECIST</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monotherapy Period: Number of Patients With Adverse Events (AEs)</measure>
    <time_frame>From start of study drug administration up to survival follow-up (up to 36 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combination Therapy Period: Arm A and B: Number of Patients With Adverse Events (AEs)</measure>
    <time_frame>From start of study drug administration up to survival follow-up (up to 36 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combination Therapy Period: Arm C: Overall Response Rate (ORR) as Assessed by RECIST 1.1</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Non-Small Cell Lung Carcinoma (NSCLC)</condition>
  <condition>Colorectal Cancer (CRC)</condition>
  <condition>Other Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Monotherapy: Normal Hepatic Function (Selinexor)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1:&#xD;
Week 1: selinexor 5 x 20-mg tablet daily;&#xD;
Week 2: selinexor 1 x 100-mg tablet daily&#xD;
Cohort 2:&#xD;
Week 1: selinexor 1 x 100-mg tablet daily;&#xD;
Week 2: selinexor 5 x 20-mg tablet daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Monotherapy: Impaired Hepatic Function (Selinexor)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 3:&#xD;
Patients with Moderate Hepatic Impairment with any Solid Tumors; - Selinexor 2 x 20-mg tablet once weekly (QW);&#xD;
Cohort 4:&#xD;
Patients with Severe Hepatic Impairment with any Solid Tumors;&#xD;
- Selinexor 2 x 20-mg tablet QW.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination Therapy: NSCLC Arm A: (Selinexor + Docetaxel)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Selinexor 60 mg oral dose QW and docetaxel 75 mg/m^2 intravenously (IV) once every 3 weeks (Non-small cell lung cancer [NSCLC] patients).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination Therapy: CRC Arm B: (Selinexor + Pembrolizumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Selinexor 80 mg oral does QW and pembrolizumab 200 mg IV every 3 weeks (Colorectal cancer [CRC] Patients).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination Therapy: CRC Arm C: (Selinexor + FOLFIRI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1:&#xD;
Selinexor 40 mg oral dose Days 1, 3, 15 and 18 in a 28-day cycle and FOLFIRI (irinotecan 180 mg/m^2; leucovorin 400 mg/m^2; 5- fluorouracil (5-FU) 400 mg/m^2 bolus then 5-FU 2400 mg/m^2 continuous over 46-48 hours; IV on Day 1 and 15 in a 28-day cycle) (CRC Patients).&#xD;
Cohort 2:&#xD;
Selinexor 80 mg oral dose Days 1 and 15 in a 28-day cycle and FOLFIRI (irinotecan 180 mg/m^2; leucovorin 400 mg/m^2; 5-FU 400 mg/m^2 bolus then 5-FU 2400 mg/m^2 continuous over 46-48 hours; IV on Day 1 and 15 in a 28-day cycle) (CRC Patients).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selinexor 100 mg</intervention_name>
    <description>100-mg 2 formulations:&#xD;
5 × 20-mg tablets (Tablet A)&#xD;
1 × 100-mg tablet (Tablet B)</description>
    <arm_group_label>Monotherapy: Normal Hepatic Function (Selinexor)</arm_group_label>
    <other_name>Xpovio®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>75 mg/m^2 IV</description>
    <arm_group_label>Combination Therapy: NSCLC Arm A: (Selinexor + Docetaxel)</arm_group_label>
    <other_name>Taxotere®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>200 mg IV</description>
    <arm_group_label>Combination Therapy: CRC Arm B: (Selinexor + Pembrolizumab)</arm_group_label>
    <other_name>Keytruda®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFIRI</intervention_name>
    <description>FOLFIRI:&#xD;
Irinotecan 180 mg/m^2&#xD;
Leucovorin 400 mg/m^2&#xD;
5-FU 400 mg/m^2 bolus&#xD;
5-FU 2400 mg/m^2 IV</description>
    <arm_group_label>Combination Therapy: CRC Arm C: (Selinexor + FOLFIRI)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selinexor 40 mg</intervention_name>
    <description>- 2 × 20-mg tablets (Tablet A)</description>
    <arm_group_label>Combination Therapy: CRC Arm C: (Selinexor + FOLFIRI)</arm_group_label>
    <arm_group_label>Monotherapy: Impaired Hepatic Function (Selinexor)</arm_group_label>
    <other_name>Xpovio®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selinexor 80 mg</intervention_name>
    <description>- 4 × 20-mg tablets (Tablet A)</description>
    <arm_group_label>Combination Therapy: CRC Arm B: (Selinexor + Pembrolizumab)</arm_group_label>
    <arm_group_label>Combination Therapy: CRC Arm C: (Selinexor + FOLFIRI)</arm_group_label>
    <other_name>Xpovio®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selinexor 60 mg</intervention_name>
    <description>- 3× 20-mg tablets (Tablet A)</description>
    <arm_group_label>Combination Therapy: NSCLC Arm A: (Selinexor + Docetaxel)</arm_group_label>
    <other_name>Xpovio®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
        Common inclusion criteria for all patients:&#xD;
&#xD;
          1. Are greater than or equal to [≥] 18 years of age at the time of informed consent.&#xD;
&#xD;
          2. Have histologically confirmed solid tumor (any type of advanced or metastatic solid&#xD;
             tumor for the Hepatic Impairment Arm of the Monotherapy Part), advanced or metastatic&#xD;
             NSCLC or CRC and evidence of measurable disease per Response Evaluation Criteria in&#xD;
             Solid Tumors (RECIST v1.1).&#xD;
&#xD;
          3. Willing to provide signed written informed consent in accordance with federal, local,&#xD;
             and institutional guidelines and comply with all requirements of the study.&#xD;
&#xD;
          4. Female patient of childbearing potential must have a negative serum pregnancy test at&#xD;
             screening and agree to use highly effective (dual methods of) contraception throughout&#xD;
             the study and for 4 months following the last dose of study drug; and male patients&#xD;
             must use an effective barrier method of contraception throughout the study and for 4&#xD;
             months following the last dose of study drug if sexually active. Male patients must&#xD;
             agree not to donate sperm during the study treatment period.&#xD;
&#xD;
             For the Monotherapy Part only (bioavailability/bioequivalence [BA/BE] and hepatic&#xD;
             impairment [HI] arms):&#xD;
&#xD;
          5. Have received at least 1 line of systemic anticancer treatment unless there is no&#xD;
             first-line standard of care therapy or standard of care therapy is contraindicated&#xD;
             adjuvant or neoadjuvant therapy is not counted as one line of systemic therapy).&#xD;
             Patients must have failed prior standard curative therapy for their disease, must be&#xD;
             intolerant to or be ineligible for any potentially curative approved treatment,&#xD;
             irrespective of line of therapy.&#xD;
&#xD;
          6. Must have either normal hepatic function, or moderate or severe hepatic impairment (as&#xD;
             defined by the NCI organ dysfunction working group (NCI-ODWG) criteria:&#xD;
&#xD;
               1. S20-100 and S100-20 arms: normal hepatic function (total bilirubin and aspartate&#xD;
                  aminotransferase [AST] less than or equal to [≤] upper limit of normal [ULN]).&#xD;
&#xD;
                  Note: Patients with mild hepatic dysfunction (total bilirubin greater than [&gt;] 1&#xD;
                  to 1.5 × ULN or AST &gt; ULN) may be included if liver function tests are stable for&#xD;
                  the past 3 months and enrollment is approved in writing by the Sponsor's Medical&#xD;
                  Monitor.&#xD;
&#xD;
               2. MHI arm: ≥1 week of documented moderate hepatic impairment (total bilirubin&#xD;
                  &gt;1.5-3 × ULN, any level of AST).&#xD;
&#xD;
               3. SHI arm: ≥1 week of documented severe hepatic impairment (total bilirubin &gt;3-10 ×&#xD;
                  ULN, any level of AST).&#xD;
&#xD;
             For Combination Therapy Part only:&#xD;
&#xD;
          7. Previous treatment lines (adjuvant or neoadjuvant therapy is not counted as one line&#xD;
             of systemic therapy):&#xD;
&#xD;
               1. Arm A: For patients with NSCLC, have received 1-2 prior lines of systemic&#xD;
                  anti-cancer treatment with 1 regimen including an anti-PD-1/L1 monoclonal&#xD;
                  antibody (mAb)&#xD;
&#xD;
               2. Arm B: For patients with RAS mutant CRC, 1-2 prior lines of systemic treatments,&#xD;
                  and no prior anti- programmed cell death protein 1/L1 monoclonal antibody&#xD;
                  (anti-PD-1/L1 mAb).&#xD;
&#xD;
                    -  KRAS WT: have 1-3 prior lines of systemic treatments.&#xD;
&#xD;
                    -  KRAS mutant (at least 50 percent [%] of patients): 1-2 prior lines of&#xD;
                       systemic treatments.&#xD;
&#xD;
               3. Arm C: For patients with CRC participating in the combination arm with FOLFIRI,&#xD;
                  1-2 prior lines of systemic therapy are allowed.&#xD;
&#xD;
               4. Arm B and C in CRC: patient with CRC who are not candidates for curative&#xD;
                  resection of metastatic lesions.&#xD;
&#xD;
          8. Must have hepatic function as follows:&#xD;
&#xD;
               1. Arm A (combination with docetaxel): patients with NSCLC who are to receive&#xD;
                  docetaxel and have bilirubin ≤ ULN, and AST and/or alanine transaminase (ALT) ≤&#xD;
                  1.5 x ULN.&#xD;
&#xD;
               2. Arm B and C: total bilirubin ≤ 1.5 × ULN and AST ≤ 2.5 x ULN, AST ≤ 2.5 x ULN;&#xD;
                  for Arm B, unless bilirubin elevation is related to Gilbert's Syndrome for which&#xD;
                  bilirubin must be ≤ 4 x ULN.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
        Common exclusion criteria for all patients:&#xD;
&#xD;
          1. Have inadequate hematopoietic function defined as (without transfusion or growth&#xD;
             factor support within 7 days prior to first dose):&#xD;
&#xD;
             a. absolute neutrophil count (ANC) &lt;1.5 × 109/liter (L); platelet count (PLT) &lt;100 ×&#xD;
             109/L; or hemoglobin (Hb) &lt;9 gram per deciliter (g/dL).&#xD;
&#xD;
          2. Have inadequate renal function defined as a calculated creatinine clearance (CrCl) of&#xD;
             &lt;20 mL/min using the formula of Cockcroft and Gault.&#xD;
&#xD;
          3. Have any other medical condition especially any gastrointestinal (GI) dysfunctions or&#xD;
             GI disease that could interfere with the absorption of selinexor (e.g., inability to&#xD;
             swallow or retain oral medications, malabsorption syndrome, a history of GI surgery&#xD;
             which may result in intestinal blind loop, significant gastroparesis, unresolved&#xD;
             nausea, vomiting, or diarrhea [National Cancer Institute (NCI) Common Terminology&#xD;
             Criteria for Adverse Events (CTCAE) Grade &gt;1]).&#xD;
&#xD;
          4. Ongoing infection requiring parenteral antibiotics, antivirals, or antifungals on Day&#xD;
             1 dosing.&#xD;
&#xD;
          5. Prior exposure to a SINE compound or selinexor.&#xD;
&#xD;
          6. Insufficient time since or not recovered from procedures or anti-cancer therapy,&#xD;
             defined as:&#xD;
&#xD;
               1. Not recovered from major surgery ≤21 days prior to Day 1 dosing. Minor&#xD;
                  procedures, such as biopsies, dental work, or placement of a port or intravenous&#xD;
                  (IV) line for infusion are permitted.&#xD;
&#xD;
               2. Have ongoing clinically significant anti-cancer therapy-related toxicities CTCAE&#xD;
                  Grade &gt;1. Patients with any of the following will not be excluded: immune&#xD;
                  checkpoint-related endocrinopathies that are well controlled with hormonal&#xD;
                  supplements, patients with electrolyte abnormalities that are well-managed with&#xD;
                  supplementation, patients with Grade 2 lymphopenia, or patients with alopecia of&#xD;
                  any grade. In specific cases, patients whose toxicity has stabilized or with&#xD;
                  Grade 2 non-hematologic toxicities can be allowed following documented approval&#xD;
                  by the Sponsor's Medical Monitor.&#xD;
&#xD;
               3. Had last dose of previous anti-cancer therapy ≤14 days prior to Day 1 dosing.&#xD;
&#xD;
               4. Palliative radiotherapy &gt;14 days prior to the study is allowed.&#xD;
&#xD;
               5. Received investigational drugs in other clinical trials within 28 days, or 5&#xD;
                  half-lives of the investigational drug (whichever is shorter), prior to Cycle 1&#xD;
                  Day 1 (C1D1).&#xD;
&#xD;
          7. Serious active psychiatric or active medical condition that could interfere with&#xD;
             participation in the study or in the opinion of the Investigator would make study&#xD;
             involvement unreasonably hazardous.&#xD;
&#xD;
          8. In the opinion of the Investigator, patients who are below their ideal body weight and&#xD;
             would be unduly impacted by changes in their weight.&#xD;
&#xD;
          9. Known allergy to selinexor (all patients), docetaxel (NSCLC Arm A only), pembrolizumab&#xD;
             (CRC arm B only), OR 5-FU, leucovorin, or irinotecan (CRC Arm C only).&#xD;
&#xD;
         10. Female patients who are pregnant or breastfeeding. For Monotherapy Part only (BA/BE&#xD;
             and HI arms):&#xD;
&#xD;
         11. Have an Eastern Cooperative Oncology Group (ECOG) performance status of:&#xD;
&#xD;
               1. ≥3 for patients to be enrolled into the S20-100 or S100-20 arms of the study.&#xD;
&#xD;
               2. ≥4 for patients to be enrolled into the MHI and SHI arms of the study.&#xD;
&#xD;
         12. For MHI and SHI arms: ANC &lt;1 × 109/L; PLT &lt;75 × 109/L; or Hb &lt;8 g/dL.&#xD;
&#xD;
         13. Received strong cytochrome P450 3A (CYP3A) inhibitors ≤7 days prior to Day 1 dosing OR&#xD;
             strong CYP3A inducers ≤14 days prior to Day 1 dosing.&#xD;
&#xD;
         14. Inability or unwillingness to undergo a series of PK sampling.&#xD;
&#xD;
             For Combination Therapy Part only:&#xD;
&#xD;
         15. Have an Eastern Cooperative Oncology Group (ECOG) performance status of ≥3 for Arms A&#xD;
             and B and ECOG PS ≥2 for Arm C.&#xD;
&#xD;
         16. Arm B patients with CRC who are to receive pembrolizumab:&#xD;
&#xD;
               1. Had a diagnosis of immunodeficiency or are receiving systemic steroid therapy&#xD;
                  (&gt;10 milligram per day [mg/day] of prednisone or equivalent) or any other form of&#xD;
                  immunosuppressive therapy.&#xD;
&#xD;
               2. Patients with controlled diabetes mellitus and patients with endocrinopathies on&#xD;
                  stable hormone replacement therapy, are eligible for the trial.&#xD;
&#xD;
               3. Have active autoimmune disease requiring systemic treatment during the past 2&#xD;
                  years. Type 1 diabetes mellitus, hypothyroidism only requiring hormone&#xD;
                  replacement skin disorders (such as vitiligo, psoriasis, or alopecia) not&#xD;
                  requiring systemic treatment, or conditions not expected to recur in the absence&#xD;
                  of an external trigger are permitted.&#xD;
&#xD;
                  Note: The Investigator needs to evaluate the patient's medical history to confirm&#xD;
                  that they are eligible to receive the combination with pembrolizumab per these&#xD;
                  criteria.&#xD;
&#xD;
               4. For patients with CRC who have received live-attenuated vaccine against an&#xD;
                  infectious disease (e.g., nasal spray influenza vaccine) ≤14 days prior to the&#xD;
                  intended C1D1 of the Combination Therapy.&#xD;
&#xD;
         17. Arm C: Patients with known dihydropyrimidine dehydrogenase (DPD) deficiency. Note: for&#xD;
             patients who are initially enrolled onto the BA/BE arm in the monotherapy part and&#xD;
             plan to switch to combination therapy after completing the planned dosing and PK&#xD;
             sample collection, dose interruption between the Monotherapy Part and the Combination&#xD;
             Therapy Part is allowed for recovery from AEs. Patients requiring &gt;21 days to recover&#xD;
             from toxicities related to selinexor should be discussed with the Sponsor's Medical&#xD;
             Monitor for documented approval to continue to the Combination Therapy Part if&#xD;
             inclusion/exclusion criteria are met. Experiencing PD during the Monotherapy Part does&#xD;
             not constitute exclusion from the Combination Therapy Part.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Kauffman, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Karyopharm Therapeutics Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Kauffman, MD, PhD</last_name>
    <phone>(617) 658-0600</phone>
    <email>mkauffman@karyopharm.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sharon Shacham, PhD, MBA</last_name>
    <phone>(617) 658-0600</phone>
    <email>sshacham@karyopharm.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Oncology &amp; Hematology Division Emek Medical Center</name>
      <address>
        <city>Afula</city>
        <zip>1834111</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gil Bar-Sela, MD</last_name>
      <phone>972-54-6459510</phone>
      <email>gil_ba@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Gil Bar-Sela, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Assuta Ashdod</name>
      <address>
        <city>Ashdod</city>
        <zip>7747629</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Larissa Ryvo, MD</last_name>
      <phone>972 72 3398126</phone>
      <email>larisar@assuta.co.il</email>
    </contact>
    <investigator>
      <last_name>Larissa Ryvo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology Department - Barzilai Medical Center</name>
      <address>
        <city>Ashkelon</city>
        <zip>7830604</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tatiana Harakovsky, MD</last_name>
      <phone>972 8-6745378</phone>
      <email>Tatianah@bmc.gov.il</email>
    </contact>
    <investigator>
      <last_name>Tatiana Harakovsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Soroka University Medical Center</name>
      <address>
        <city>Beer-Sheva</city>
        <zip>84101</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oncology Department Hillel Yaffe Medical Center</name>
      <address>
        <city>Hadera</city>
        <zip>38100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Valerya Seminesty, MD</last_name>
      <phone>972 4-7748280, 972 50 2066127</phone>
      <email>ValeryS@hy.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Valerya Seminesty, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bnei Zion Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>31048</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Abed Agbarya, MD</last_name>
      <phone>972 50-2062679</phone>
      <email>abed.agbarya@b-zion.org.il</email>
    </contact>
    <investigator>
      <last_name>Abed Agbarya, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care Campus</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Talia Shentzer Kutiel, MD</last_name>
      <phone>972 4 7776473</phone>
      <email>t_shentzer@rambam.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Talia Shentzer Kutiel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shaarei Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>9103102</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nir Peled, MD</last_name>
      <phone>972 2 5645201</phone>
      <email>nirp@szmc.org.il</email>
    </contact>
    <investigator>
      <last_name>Nir Peled, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hadassah Ein Karem University Hospital</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aviad Zick, MD</last_name>
      <phone>972 2 6776725</phone>
      <email>aviadz@hadassah.org.il</email>
    </contact>
    <investigator>
      <last_name>Aviad Zick, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Meir Medical Center</name>
      <address>
        <city>Kfar Saba</city>
        <zip>4428164</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maya Gottfried, MD</last_name>
      <phone>972 9 7472414</phone>
      <email>Maya.Gottfried@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Maya Gottfried, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Galilee Medical Center</name>
      <address>
        <city>Nahariya</city>
        <zip>22100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ayelet Shai, MD</last_name>
      <phone>972 4 9107149</phone>
      <email>AyeletS@gmc.gov.il</email>
    </contact>
    <investigator>
      <last_name>Ayelet Shai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petach Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Idit Peretz, MD</last_name>
      <phone>972-50-2024755</phone>
      <email>iditper@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Idit Peretz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tel-Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ravit Geva, MD</last_name>
      <phone>972 3 6972966</phone>
      <email>ravitg@tlvmc.gov.il</email>
    </contact>
    <investigator>
      <last_name>Ravit Geva, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Tel-Hashomer</city>
        <zip>5265601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Talia Golan, MD</last_name>
      <phone>972 3 5305338</phone>
      <email>Talia.Golan@sheba.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Talia Golan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 3, 2020</study_first_submitted>
  <study_first_submitted_qc>February 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-small cell lung carcinoma</keyword>
  <keyword>Selinexor</keyword>
  <keyword>Docetaxel</keyword>
  <keyword>Colorectal cancer</keyword>
  <keyword>KPT-330</keyword>
  <keyword>Bioequivalence</keyword>
  <keyword>Relative bioavailability</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Other Solid Tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

